Work

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2013-lb-147

Authors: Jeffrey R. Infante, Leena Gandi, Geoffrey Shapiro, Naiyer Rizvi, Howard A. Burris, Johanna C. Bendell, José Baselga, Karl Hsu, Oliver von Richter, Giuseppe Locatelli, Ekaterine Asatiani, Rebecca S. Heist

Institutions: Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Merck KGaA, Darmstadt (Germany), Merck Serono S.A. (Switzerland)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2090657374

Cites:

Cited by: 18

Related to: 10